文献速递神经肿瘤

溶瘤病毒治疗胶质母细胞瘤患者诱导肿瘤巨噬细胞表型转变并改变胶质母细胞瘤微环境

Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
PubMed 文献 · Neuro Oncol · 2018-01-01

研究通过体外模型和患者标本,探讨溶瘤病毒Delta24-RGD对人胶质母细胞瘤(GBM)中巨噬细胞表型的影响。结果显示,与感染Delta24-RGD的胶质瘤干细胞样细胞共培养可使M2巨噬细胞向M1表型转变,并伴随促炎基因表达和细胞因子分泌;18例治疗患者脑脊液细胞因子水平提示促炎微环境;1例治疗患者肿瘤巨噬细胞M1特征显著高于5例对照。结论认为局部Delta24-RGD治疗可能促进M2向M1的持续转变,诱导促炎且可能对肿瘤不利的微环境。

要点

  • Delta24-RGD感染的胶质瘤干细胞样细胞可诱导M2巨噬细胞向M1免疫表型转变。
  • 18例Delta24-RGD治疗患者脑脊液细胞因子水平提示促炎微环境。
  • 1例治疗患者肿瘤巨噬细胞M1特征显著高于5例对照GBM组织。

核心结论

  • 体外和患者研究共同表明,局部Delta24-RGD治疗可能促进人GBM中促肿瘤M2巨噬细胞向M1的持续转变,诱导促炎且可能对肿瘤不利的微环境。

研究设计与样本

  • 研究采用体外模型和患者材料,包括人单核细胞来源巨噬细胞与Delta24-RGD感染的胶质瘤干细胞样细胞共培养,分析18例Delta24-RGD治疗患者脑脊液细胞因子,以及比较1例治疗患者与5例对照GBM患者手术标本中的肿瘤巨噬细胞。

主要发现

  • 与Delta24-RGD感染的胶质瘤干细胞样细胞共培养的人单核细胞来源M2巨噬细胞向M1免疫表型转变,并伴随促炎基因表达和细胞因子产生。
  • 该表型转变由肿瘤产生的可溶性因子改变和病毒颗粒存在的协同作用诱导。
  • 18例Delta24-RGD治疗的GBM患者脑脊液样本细胞因子水平提示促炎微环境。
  • 1例Delta24-RGD治疗患者的肿瘤巨噬细胞M1特征显著高于5例对照GBM组织。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunosuppressive protumoral M2 macrophages are important in pathogenesis, progression, and therapy resistance in glioblastoma (GBM) and provide a target for therapy. Recently oncolytic virotherapy in murine models was shown to change these M2 macrophages toward the pro-inflammatory and antitumoral M1 phenotype. Here we study the effects of the oncolytic virotherapy Delta24-RGD in humans, using both in vitro models and patient material. METHODS: Human monocyte-derived macrophages were co-cultured with Delta24-RGD-infected primary glioma stem-like cells (GSCs) and were analyzed for their immunophenotype, cytokine expression, and secretion profiles. Cerebrospinal fluid (CSF) from 18 Delta24-RGD-treated patients was analyzed for inflammatory cytokine levels, and the effects of these CSF samples on macrophage phenotype in vitro were determined. In addition, tumor macrophages in resected material from a Delta24-RGD-treated GBM patient were compared with 5 control GBM patient samples by flow cytometry. RESULTS: Human monocyte-derived M2 macrophages co-cultured with Delta24-RGD-infected GSCs shifted toward an M1-immunophenotype, coinciding with pro-inflammatory gene expression and cytokine production. This phenotypic switch was induced by the concerted effects of a change in tumor-produced soluble factors and the presence of viral particles. CSF samples from Delta24-RGD-treated GBM patients revealed cytokine levels indicative of a pro-inflammatory microenvironment. Furthermore, tumoral macrophages in a Delta24-RGD-treated patient showed significantly greater M1 characteristics than in control GBM tissue. CONCLUSION: Together these in vitro and patient studies demonstrate that local Delta24-RGD therapy may provide a therapeutic tool to promote a prolonged shift in the protumoral M2 macrophages toward M1 in human GBM, inducing a pro-inflammatory and potentially tumor-detrimental microenvironment.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. van den Bossche WBL, Kleijn A, Teunissen CE, et al. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. Neuro Oncol. 2018. PMID: 29796615. doi:10.1093/neuonc/noy082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。